Adamis Pharmaceuticals Corporation (ADMP) stock declined over -1.01% intraday to trade at $0.53 a share on NASDAQ. The stock opened with a gain of 20.45% at $0.533 and touched an intraday high of $0.54, rising 0.00% against the last close of $0.53. The stock went to a low of $0.513 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue2.21 Million
5Y Sales Change-19.40%
Fiscal Year Ends2021-12-30
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) stock price is $0.53 as of the last check on Wednesday, July 6. During the trading session, ADMP stock reached the peak price of $0.54 while $0.513 was the lowest point it dropped to.
The NASDAQ listed ADMP is part of Pharmaceuticals industry that operates in the broader Health Care sector. Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose.
Dr. Dennis J. Carlo
Pres, CEO & Director
Mr. David J. Marguglio
Sr. VP, Chief Bus. Officer & Director
Dr. Ronald B. Moss
Chief Medical Officer
Mr. David C. Benedicto
Chief Financial Officer
ADMP stock traded closed the last session at $0.528, which is $0.00 or -1.01% lower than its previous close of $0.53. ADMP's current trading price is 69.28% lower than its 52-week high of $1.48 where as its distance from 52-week low of 0.31% is -64.34%.
Number of ADMP employees currently stands at -. ADMP operates from 11682 El Camino Real, Suite 300, San Diego, CA 92130, United States.
Official Webiste of $ADMP is: https://www.adamispharmaceuticals.com
ADMP stock volume for the day was 354,449 shares while in the previous session number of ADMP shares traded was 352,584 . The average number of ADMP shares traded daily for last 3 months was 682.83 Thousands.
The percentage change in ADMP stock occurred in the recent session was -1.01% while the dollar amount for the price change in ADMP stock was $0.00.
In the recent session, the day high for ADMP stock was $0.54 while the low for ADMP stock touched on the day was $0.513.
The market value of ADMP currently stands at 79.17 Million with its latest stock price at $0.53 and 149.62 Million of its shares outstanding.